LifeVantage Corporation (FRA:L2T1)

Market Cap	56.66M -81.0%
Revenue (ttm)	195.07M +16.8%
Net Income	8.64M +145.1%
EPS	0.66 +143.9%
Shares Out	n/a
PE Ratio	6.56
Forward PE	4.71
Dividend	0.16 (3.45%)
Ex-Dividend Date	Dec 1, 2025

Volume	n/a
Average Volume	51
Open	4.500
Previous Close	5.400
Day's Range	4.500 - 4.500
52-Week Range	4.500 - 22.600
Beta	n/a
RSI	41.24
Earnings Date	Feb 4, 2026

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatig...

• Industry: Pharmaceutical Preparations
• CEO: Steven Fife
• Employees: 238
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: L2T1

Financial Performance

In fiscal year 2025, LifeVantage's revenue was $228.53 million, an increase of 14.17% compared to the previous year's $200.16 million. Earnings were $9.81 million, an increase of 233.84%.

Financial numbers in USD